• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.

作者信息

Jerkeman Mats, Mellgren Karin, Sonnevi Kristina, Lisak Mikael, Lagerlöf Ingemar, Kapas Balazs, Sjölund Hanna, Toporski Jacek, Hagberg Hans, Mielke Stephan, Enblad Gunilla

机构信息

Skåne University Hospital and Lund University, Lund, Sweden.

Sahlgrenska University Hospital, Gothenburg, Sweden.

出版信息

Leukemia. 2025 May;39(5):1256-1259. doi: 10.1038/s41375-025-02573-y. Epub 2025 Mar 26.

DOI:10.1038/s41375-025-02573-y
PMID:40140632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12055569/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ed/12055569/b13c5d3c2491/41375_2025_2573_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ed/12055569/b13c5d3c2491/41375_2025_2573_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ed/12055569/b13c5d3c2491/41375_2025_2573_Fig1_HTML.jpg

相似文献

1
Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.瑞典针对侵袭性B细胞淋巴瘤和急性淋巴细胞白血病患者实施嵌合抗原受体T细胞（CAR-T）治疗的护理标准。
Leukemia. 2025 May;39(5):1256-1259. doi: 10.1038/s41375-025-02573-y. Epub 2025 Mar 26.
2
[Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia].博纳吐单抗桥接嵌合抗原受体T细胞疗法治疗成人急性B淋巴细胞白血病患者的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):339-344. doi: 10.3760/cma.j.cn121090-20231127-00283.
3
Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report.患者曾接受异基因造血干细胞移植和嵌合抗原受体 T 细胞（CAR-T）治疗，现患有 B 细胞淋巴母细胞淋巴瘤/急性淋巴细胞白血病合并心脏受累：病例报告。
Front Immunol. 2023 Jan 5;13:1052336. doi: 10.3389/fimmu.2022.1052336. eCollection 2022.
4
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.嵌合抗原受体T细胞（CAR-T细胞）治疗T细胞急性淋巴细胞白血病/淋巴瘤的临床疗效与安全性
Ann Hematol. 2025 Jan;104(1):57-63. doi: 10.1007/s00277-024-06132-w. Epub 2024 Dec 18.
5
Clinical Outcomes of CD7 CAR-T Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients.CD7嵌合抗原受体T细胞疗法在复发或难治性T细胞急性淋巴细胞白血病和淋巴细胞淋巴瘤患者中的临床疗效
Hematol Oncol. 2025 May;43(3):e70081. doi: 10.1002/hon.70081.
6
[Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].[抗CD19嵌合抗原受体T细胞桥接异基因造血干细胞移植治疗难治性B淋巴细胞白血病患者的安全性和有效性]
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 14;41(3):239-244. doi: 10.3760/cma.j.issn.0253-2727.2020.03.010.
7
SOHO State of the Art Updates and Next Questions | CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.SOHO最新技术进展与后续问题 | T细胞急性淋巴细胞白血病和淋巴细胞淋巴瘤中的嵌合抗原受体T细胞
Clin Lymphoma Myeloma Leuk. 2025 Feb;25(2):77-88. doi: 10.1016/j.clml.2024.05.018. Epub 2024 May 31.
8
Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.CD19 导向嵌合抗原受体治疗 B 细胞急性淋巴细胞白血病的结局决定因素和进展。
Eur J Haematol. 2024 Jan;112(1):51-63. doi: 10.1111/ejh.14132.
9
[Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].人源化和鼠源化CD19嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的长期随访
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):793-799. doi: 10.3760/cma.j.issn.0253-2727.2023.10.001.
10
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.嵌合抗原受体T细胞及癌症T细胞疗法：转化科学综述
JAMA. 2024 Dec 10;332(22):1924-1935. doi: 10.1001/jama.2024.19462.

引用本文的文献

1
Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?CAR-T细胞治疗B细胞淋巴瘤后与长期免疫细胞相关血液毒性相关的髓系肿瘤的发生：我们应该监测是否存在预先存在的髓系突变吗？
Hemasphere. 2025 Jun 5;9(6):e70160. doi: 10.1002/hem3.70160. eCollection 2025 Jun.

本文引用的文献

1
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.标准 care 阿基卡宾替西利尤单抗治疗大 B 细胞淋巴瘤的 5 年随访结果：来自美国淋巴瘤嵌合抗原受体 T 细胞联盟的研究。
J Clin Oncol. 2024 Oct 20;42(30):3581-3592. doi: 10.1200/JCO.23.02786. Epub 2024 Aug 2.
2
Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.随着时间的推移，英国接受 CD19 CAR T 治疗的大 B 细胞淋巴瘤患者的预后得到改善。
Br J Haematol. 2024 Feb;204(2):507-513. doi: 10.1111/bjh.19157. Epub 2023 Oct 17.
3
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.
通过流式细胞术对抗CD19嵌合抗原受体T细胞进行早期定量可预测复发/难治性弥漫性大B细胞淋巴瘤的反应。
Blood Adv. 2023 Nov 28;7(22):6844-6849. doi: 10.1182/bloodadvances.2023010364.
4
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients.单细胞RNA分析揭示了嵌合抗原受体T细胞的细胞内在功能，这些功能与淋巴瘤患者II期研究中的反应相关。
Clin Cancer Res. 2023 Oct 13;29(20):4139-4152. doi: 10.1158/1078-0432.CCR-23-0178.
5
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.ELIANA 试验中复发/难治性急性淋巴细胞白血病的儿科和年轻成年患者接受 tisagenlecleucel 治疗的 3 年更新结果。
J Clin Oncol. 2023 Mar 20;41(9):1664-1669. doi: 10.1200/JCO.22.00642. Epub 2022 Nov 18.
6
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.Tisagenlecleucel 和 axicabtagene ciloleucel CAR T 细胞治疗复发或难治性弥漫性大 B 细胞淋巴瘤的真实世界比较。
Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
7
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.西达基奥仑赛对比挽救化疗后自体干细胞移植作为二线治疗复发或难治性大 B 细胞淋巴瘤患者的标准治疗（TRANSFORM）：一项开放标签、随机、3 期临床试验的中期分析结果。
Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6.
8
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.德国 GLA/DRST 真实世界研究分析嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤的结果。
Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.
9
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).成人和儿童接受嵌合抗原受体 T 细胞（CAR T）疗法的管理：欧洲血液和骨髓移植学会（EBMT）、国际干细胞治疗认证委员会和 EBMT（JACIE）联合认证委员会以及欧洲血液学协会（EHA）的 2021 年最佳实践建议。
Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16.
10
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.阿基仑赛注射液二线治疗大 B 细胞淋巴瘤。
N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11.